NCT03328026: Rollover Study of SV-BR-1-GM in Combination With Ipilimumab or Pembrolizumab

NCT03328026
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Symptomatic untreated brain metastases
https://ClinicalTrials.gov/show/NCT03328026

Comments are closed.

Up ↑